Immunotoxin therapy for primary malignant brain tumors

Keyphrases

• Immunotoxin 100%
• Primary Brain Tumor 100%
• Irradiation 80%
• Insulin-like Growth Factor 1 Receptor (IGF1R) 60%
• U373 60%
• Fusion Toxin 60%
• Daoy 60%
• Growth Factors 40%
• Cytotoxicity 40%
• Cell Surface Receptor 40%
• Interleukin-4 (IL-4) 40%
• IL-4Rα 40%
• Neuro-2a 40%
• Malignant Brain Tumor 40%
• Medulloblastoma 20%
• Insulin-like 20%
• Tumor 20%
• Tumor Cells 20%
• Recombinant 20%
• Antitumor Activity 20%
• Targeted Toxin 20%
• Glioblastoma 20%
• Human Glioblastoma 20%
• Adjuvant Therapy 20%
• Radiation Effects 20%
• Neural Tissue 20%
• Central Nervous System Tumors 20%
• Protein Synthesis 20%
• Neuroblastoma 20%
• IC50 20%
• High Specificity 20%
• Cytotoxic Effect 20%
• Aggressive Treatment 20%
• Chimeric Protein 20%
• Interleukin-4 Receptor 20%
• Diphtheria 20%
• Daoy Cells 20%
• Natural Carriers 20%
• Natural Toxins 20%
• Treatment Modalities 20%
• Toxin Therapy 20%
• Dose-dependent 20%
• Cytosol 20%
• Minimal Damage 20%
• Cytotoxic Efficacy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunotoxin 100%
• Brain Cancer 100%
• Receptor 80%
• Cytotoxicity 60%
• Glioblastoma 40%
• Cell Surface Receptor 40%
• Interleukin 4 40%
• Neoplasm 40%
• Growth Factor 20%
• Natural Toxin 20%
• Somatomedin C 20%
• Neuroblastoma 20%
• Central Nervous System Tumor 20%
• Interleukin 4 Receptor 20%
• Chimeric Protein 20%
• IC50 20%
• Diphtheria 20%
• Medulloblastoma 20%